feed,title,long_url,short_url
Benzinga,AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer,https://benzinga.com/general/biotech/24/06/39351572/astrazeneca-says-calquencechemo-combo-data-shows-additional-16-8-months-without-disease-progressi,https://da.gd/qocwoe
